NYSE:CLDI
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. reported net income of −$19.9M in fiscal 2025. The diluted share count rose 545.0%.Summary generated from Calidi Biotherapeutics, Inc.'s SEC filings. Latest annual report filed Mar 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−752.2%
Debt / equity0.16
Free cash flown/a
FCF marginn/a
Share count change+545.0%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | n/a | n/a | n/a |
| Operating income | −23 | −29 | −22 | −20 |
| Net income | −25 | −29 | −22 | −20 |
| Free cash flow | n/a | n/a | n/a | n/a |
Recent filings
- 8-KNotice of delisting or listing-rule failure
Sep 25, 2026 - 8-KEntry into a material agreement
Sep 22, 2026 - 4Insider transaction report
Aug 19, 2026 - 4Insider transaction report
Aug 19, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KAmendment to articles or bylaws
Jul 31, 2026 - 8-KEntry into a material agreement
Jul 16, 2026